Hematologic Malignancy Clinical Trials & Research at St. Joseph Health
Medical Group
St. Joseph Health Medical Group is currently enrolling patients for the
following hematologic malignancy clinical trials:
Myelofibrosis and Essential Thrombocythemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Multiple Myeloma
Myelofibrosis and Essential Thrombocythemia
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and
Treatment of Patients With Low-Risk Myelofibrosis (Mf) or High-Risk Essential
Thrombocythemia (Et) or Et Patients Receiving Et-Directed Therapy (MOST)
Treatment agent: N/A
PI:
Jarrod Holmes, MD
Study Coordinator: Catherine Hollister //
Catherine.Hollister@stjoe.org // (707) 521-3808
Resources and Links:
clinicaltrials.gov NCT No: NCT02953704
Myelodysplastic Syndrome
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating
the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia
in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red
Blood Cell (RBC) Transfusion Burden (LTB) (Fibrogen)
Treatment agent: Roxadustat
PI:
Jarrod Holmes, MD
Study Coordinator: Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03263091
Acute Myeloid Leukemia
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease
Registry (Connect MDS/AML)
Treatment agent: N/A
PI:
Thomas Stanton, MD
Study Coordinator: Diego Martinez //
Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links:
clinicaltrials.gov NCT No: NCT01688011
Chronic Lymphocytic Leukemia
A Disease Registry for Patients with Chronic Lymphocytic Leukemia (InformCLL)
Treatment agent: N/A
PI:
Wes Lee, MD
Study Coordinator: Diego Martinez //
Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links:
clinicaltrials.gov NCT No: NCT02582879
back to top
Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465,
a PI3Kδ Inhibitor, to Idelalisib in Relapsed or Refractory Follicular
Lymphoma (CITADEL 203)
Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT03126019
Marginal Zone Lymphoma
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor,
in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or
Without Prior Exposure to a BTK Inhibitor (CITADEL 204)
Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT03144674
Mantle Cell Lymphoma
A Phase 2, Open-Label, Two-Cohort, Multicenter Study of INCB050465, a PI3Kδ
Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated
With or Without a BTK Inhibitor (CITADEL 205)
Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT03235544
Diffuse Large B-Cell Lymphoma
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in
Subjects with Hematological Malignancies (JIT eFFECTOR)
Treatment agent: eFT508 (MNK1 & MNK2 inhibitor)
PI:
Thomas Stanton, MD
Study Coordinator: Kim Young //
Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links:
clinicaltrials.gov NCT No: NCT02937675
A global, prospective, non-interventional, observational study of presentation,
treatment patterns, and outcomes in multiple myeloma patients (InsightMM)
Treatment agent: N/A
PI:
Ian Anderson, MD
Study Coordinator: Diego Martinez //
Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links:
clinicaltrials.gov NCT No: NCT02761187
back to top